TransCon hGH

DRUG4 trials

Sponsors

Ascendis Pharma Growth Disorders A/S, Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma A/S, Visen Pharmaceuticals (Shanghai) Co., Ltd.

Conditions

Children with AchondroplasiaEndocrine System DiseasesGrowth Hormone DeficiencyGrowth Hormone Deficiency, PediatricHormone DeficiencyHormonesPituitary Disease, AnteriorPituitary Diseases

Phase 2

COACH: A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia

Active, not recruitingCTIS2023-508341-40-00

Ascendis Pharma Growth Disorders A/SChildren with Achondroplasia

Start: 2024-07-26Target: 10Updated: 2025-12-08

Phase 3

A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

CompletedNCT03305016

Ascendis Pharma Endocrinology Division A/SEndocrine System Diseases, Growth Hormone Deficiency, Pediatric, Hormone Deficiency +1

Start: 2017-11-13End: 2019-03-19Updated: 2026-07-07

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

CompletedNCT03344458

Ascendis Pharma A/SEndocrine System Diseases, Growth Hormone Deficiency, Pediatric, Hormone Deficiency +1

Start: 2017-12-19End: 2023-02-21Updated: 2026-07-07

Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

Visen Pharmaceuticals (Shanghai) Co., Ltd.Endocrine System Diseases, Growth Hormone Deficiency, Hormones +2

Start: 2019-12-30End: 2022-04-30Target: 150Updated: 2020-03-30

Related Papers

Once-weekly Lonapegsomatropin was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial.

2026-02-27